Immunoassays and Methods to Diagnose Syphilis by Immobilizing a Lipoidal Antigen on a Solid Support
Syphilis, a genital ulcerative disease caused by the bacterium Treponema pallidum, is associated with significant complications if left untreated. Syphilis rates in the United States have been increasing.
CDC scientists have developed a method for capturing anti-lipoidal antibodies that are produced during syphilis infection. This method works by immobilizing a lipoidal antigen including (but not limited to) cardiolipin, lecithin and cholesterol on a solid support such as a nitrocellulose membrane. When the membrane-bound lipoidal antigen is exposed to a patient serum sample, any antibodies specific for the lipoidal antigen will be captured, allowing for easy detection. Detection may be accomplished by a visual, qualitative method producing results that are easy to read and interpret. The test can be used at the point-of-care (POC), in rural areas and/or in field studies. This method is adaptable for use with other antigen-antibody interactions and diagnostics for additional diseases characterized by the presence of anti-lipoidal antibodies.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Related Invention(s):
E-310-2013-0
E-334-2013-0
E-574-2013-0
Inventors:
Arnold Castro (CDC) ➽ more inventions...
Robert George (CDC) ➽ more inventions...
Intellectual Property:
U.S. Pat: 8,389,229 issued 2013-03-05
PCT Application No. PCT/US2006/024117
US Application No. 11/993,213
US Application No. 13/421,681
Collaboration Opportunity:
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Immunoassays and Methods to Diagnose Syphilis by Immobilizing a Lipoidal Antigen on a Solid Support. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 1-404-639-1330.
Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518
OTT Reference No: E-321-2013-0
Updated: Sep 11, 2018